The application of CAR-T cell therapy provides new treatment options for patients. Clinical evidence shows that CAR-T cell therapy has achieved remarkable efficacy in hematological malignancies, with some patients even achieving complete remission. All currently approved cellular products have reported these longterm durable responses. Studies show that 83% of lymphoma patients achieve remission after receiving CAR-T cell therapy, of whom 53% achieve complete remission [2].

With the continuous development of technologies such as artificial intelligence, multi-modal image fusion, and real-time dose monitoring, the CyberKnife of the future will have a higher level of intelligence. Its faster image processing speed, more accurate motion prediction models, and more adaptive treatment plan adjustments will allow this "radiation therapy drone" to cope freely on the anti-cancer battlefield, bringing patients safer, more efficient, and non-invasive new

"Currently, our team is capable of performing almost all the world’s most advanced cardiovascular interventional diagnosis and treatment technologies, striving to provide comprehensive treatment guarantees for patients with various high-risk, difficult, and complex cardiovascular diseases," said Fu Guosheng.

Minimally Invasive Cardiovascular Surgery (MICS) is one of the fastest-developing subspecialties in cardiovascular surgery. Due to less trauma, fewer complications, and faster recovery, MICS is a key development direction. The China National Minimally Invasive Cardiovascular Surgery Professional Committee (CMICS) promotes aligning domestic techniques with international standards. The goal is to summarize MICS progress in China, its clinical effects, and future trends.